+

WO2002055071A1 - Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols - Google Patents

Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols Download PDF

Info

Publication number
WO2002055071A1
WO2002055071A1 PCT/IB2001/000256 IB0100256W WO02055071A1 WO 2002055071 A1 WO2002055071 A1 WO 2002055071A1 IB 0100256 W IB0100256 W IB 0100256W WO 02055071 A1 WO02055071 A1 WO 02055071A1
Authority
WO
WIPO (PCT)
Prior art keywords
tocotrienol
group
cholesterol
administering
pharmaceutical composition
Prior art date
Application number
PCT/IB2001/000256
Other languages
English (en)
Other versions
WO2002055071A8 (fr
Inventor
Najla Guthrie
Elzbieta Maria Kurowska
Original Assignee
Kgk Synergize
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kgk Synergize filed Critical Kgk Synergize
Priority to PCT/IB2001/000256 priority Critical patent/WO2002055071A1/fr
Priority to AU2001232182A priority patent/AU2001232182A1/en
Publication of WO2002055071A1 publication Critical patent/WO2002055071A1/fr
Publication of WO2002055071A8 publication Critical patent/WO2002055071A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention concerne une composition et des méthodes permettant de prévenir et de traiter l'hypercholestérolémie, l'hyperlipidémie et l'athérosclérose. Des individus présentant un risque élevé de développer ou de contracter l'hypercholestérolémie et l'athérosclérose, et suivant des thérapies classiques, peuvent être traités à l'aide d'une dose efficace de dérivés triperpènes contenus dans des composés de limonoïdes, de flavonoïdes polyphénoliques, dans des tocotriénols ou dans une combinaison de ces agents.
PCT/IB2001/000256 2001-01-15 2001-01-15 Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols WO2002055071A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2001/000256 WO2002055071A1 (fr) 2001-01-15 2001-01-15 Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols
AU2001232182A AU2001232182A1 (en) 2001-01-15 2001-01-15 Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/000256 WO2002055071A1 (fr) 2001-01-15 2001-01-15 Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols

Publications (2)

Publication Number Publication Date
WO2002055071A1 true WO2002055071A1 (fr) 2002-07-18
WO2002055071A8 WO2002055071A8 (fr) 2002-08-15

Family

ID=11004047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000256 WO2002055071A1 (fr) 2001-01-15 2001-01-15 Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols

Country Status (2)

Country Link
AU (1) AU2001232182A1 (fr)
WO (1) WO2002055071A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087567A3 (fr) * 2001-05-02 2002-12-27 Kgk Synergize Inc Utilisation de flavones polymethoxylees afin de traiter l'insulinoresistance
WO2005115377A1 (fr) * 2004-05-26 2005-12-08 Kgk Synergize Inc Aliments fonctionnels comprenant des flavonoides et des tocotrienols et procedes associes
WO2005115378A1 (fr) * 2004-05-26 2005-12-08 Kgk Synergize Inc Compositions contenant des flavonoides et des tocotrienols et methodes associees
WO2007093853A3 (fr) * 2005-11-10 2008-01-10 Kgk Synergize Inc Compositions et méthodes de traitement et prévention du syndrome métabolique et des troubles par des combinaison de limonoïdes, flavonoïdes et tocotriénols
WO2008021368A2 (fr) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions et méthodes de neuroprotection
US7683095B2 (en) 1998-10-06 2010-03-23 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
US9573919B2 (en) 2004-11-08 2017-02-21 Arkray, Inc. Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same
US9610276B2 (en) 2013-06-17 2017-04-04 Kgk Synergize, Inc. Compositions and methods for glycemic control of subjects with impaired fasting glucose

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603142A (en) * 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
US5348974A (en) * 1989-10-04 1994-09-20 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
WO1998016239A1 (fr) * 1996-10-14 1998-04-23 Korea Institute Of Science And Technology EXTRAIT D'ECORCE DE CITRUS UTILISE EN TANT QU'INHIBITEUR DE 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A (HMG CoA) REDUCTASE
WO1999015167A2 (fr) * 1997-09-26 1999-04-01 Kgk Synergize Inc. Utilisation de limonoides et de flavonoides d'agrumes et de tocotrienols pour le traitement du cancer
WO1999021570A1 (fr) * 1997-10-28 1999-05-06 Korea Institute Of Science And Technology Extrait d'ecorce d'agrumes en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophage-lipide sur les parois arterielles et agent de prevention ou de traitement des maladies hepatiques
WO2000002553A1 (fr) * 1998-07-08 2000-01-20 Lipogenics, Inc. Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603142A (en) * 1984-06-01 1986-07-29 Wisconsin Alumni Research Foundation Cholesterol lowering method of use
US5348974A (en) * 1989-10-04 1994-09-20 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
WO1998016239A1 (fr) * 1996-10-14 1998-04-23 Korea Institute Of Science And Technology EXTRAIT D'ECORCE DE CITRUS UTILISE EN TANT QU'INHIBITEUR DE 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A (HMG CoA) REDUCTASE
WO1999015167A2 (fr) * 1997-09-26 1999-04-01 Kgk Synergize Inc. Utilisation de limonoides et de flavonoides d'agrumes et de tocotrienols pour le traitement du cancer
WO1999021570A1 (fr) * 1997-10-28 1999-05-06 Korea Institute Of Science And Technology Extrait d'ecorce d'agrumes en tant qu'inhibiteur d'acyle coa-cholesterol-o-acyltransferase, inhibiteur de l'accumulation du complexe macrophage-lipide sur les parois arterielles et agent de prevention ou de traitement des maladies hepatiques
WO2000002553A1 (fr) * 1998-07-08 2000-01-20 Lipogenics, Inc. Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BORRADAILE, N. ET AL: "Regulatory effects of citrus flavonoids on apo B metabolism in HepG2 cells.", FASEB JOURNAL, ( MARCH 17, 1998 ) VOL. 12, NO. 4, PP. A207. MEETING INFO.: ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 98, PART 1 SAN FRANCISCO, CALIFORNIA, USA APRIL 18-22, 1998 FEDERATION OF AMERICAN SOCIETIES FOR, XP000999743 *
CARROLL, KENNETH K. ET AL: "Anticancer properties of flavonoids, with emphasis on citrus flavonoids", ANTIOXID. HEALTH DIS. (1998), 7(FLAVONOIDS IN HEALTH AND DISEASE), 437-446, XP001000063 *
GUTHRIE ET AL: "Abstract 1907: combined effect of palm oil tocotrienols, flavonoids and tamoxifen on the prolferation of estrogen receptor-positive MCF-7 human breast cancer cells", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. MEETING 87, March 1996 (1996-03-01), pages 280, XP002099426, ISSN: 0197-016X *
GUTHRIE, N. ET AL: "In vitro studies on anti-cancer and cholesterol-lowering activities of citrus flavonoids and limonoids.", FASEB JOURNAL, ( MARCH 15, 2000 ) VOL. 14, NO. 4, PP. A563. PRINT. MEETING INFO.: ANNUAL MEETING OF PROFESSIONAL RESEARCH SCIENTISTS: EXPERIMENTAL BIOLOGY 2000 SAN DIEGO, CALIFORNIA, USA APRIL 15-18, 2000 FEDERATION OF AMERICAN SOCIETIES FOR EXPERIME, XP000996472 *
KUROWSKA, E. M. (1) ET AL: "Role of tocotrienols from palm oil in regulation of APO B metabolism in HEPG2 cells.", FASEB JOURNAL, ( MARCH 12, 1999 ) VOL. 13, NO. 4 PART 1, PP. A562. MEETING INFO.: ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS FOR EXPERIMENTAL BIOLOGY 99 WASHINGTON, D.C., USA APRIL 17-21, 1999, XP000999072 *
KUROWSKA, ELZBIETA M. (1) ET AL: "Regulation of apo B production in HEPG2 cells by citrus limonoids.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (1999) VOL. 217, NO. 1-2, PP. AGFD 57. MEETING INFO.: 217TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY ANAHEIM, CALIFORNIA, USA MARCH 21-25, 1999 AMERICAN CHEMICAL SOCIETY., XP000999731 *
KUROWSKA, ELZBIETA M. (1) ET AL: "Regulation of lipoprotein metabolism in HepG2 cells by citrus flavonoids.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (2000) VOL. 219, NO. 1-2, PP. AGFD 169. MEETING INFO.: 219TH MEETING OF THE AMERICAN CHEMICAL SOCIETY. SAN FRANCISCO, CALIFORNIA, USA MARCH 26-30, 2000 AMERICAN CHEMICAL SOCIETY., XP000999740 *
KUROWSKA, ELZBIETA M. ET AL: "Regulation of apo B production in HepG2 cells by citrus limonoids", ACS SYMP. SER. (2000), 758(CITRUS LIMONOIDS), 175-184, XP000996481 *
ROBBINS, RALPH C.: "Effect of flavonoids on survival time of rats fed thrombogenic or atherogenic regimens", J. ATHEROSCLER. RES. (1967), 7(1), 3-10, XP000996769 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683095B2 (en) 1998-10-06 2010-03-23 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
WO2002087567A3 (fr) * 2001-05-02 2002-12-27 Kgk Synergize Inc Utilisation de flavones polymethoxylees afin de traiter l'insulinoresistance
WO2005115377A1 (fr) * 2004-05-26 2005-12-08 Kgk Synergize Inc Aliments fonctionnels comprenant des flavonoides et des tocotrienols et procedes associes
WO2005115378A1 (fr) * 2004-05-26 2005-12-08 Kgk Synergize Inc Compositions contenant des flavonoides et des tocotrienols et methodes associees
EP1748774A4 (fr) * 2004-05-26 2007-12-19 Kgk Synergize Inc Compositions contenant des flavonoides et des tocotrienols et methodes associees
EP1748773A4 (fr) * 2004-05-26 2008-11-12 Kgk Synergize Inc Aliments fonctionnels comprenant des flavonoides et des tocotrienols et procedes associes
US9573919B2 (en) 2004-11-08 2017-02-21 Arkray, Inc. Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same
WO2007093853A3 (fr) * 2005-11-10 2008-01-10 Kgk Synergize Inc Compositions et méthodes de traitement et prévention du syndrome métabolique et des troubles par des combinaison de limonoïdes, flavonoïdes et tocotriénols
WO2008021368A2 (fr) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions et méthodes de neuroprotection
EP2056818A4 (fr) * 2006-08-11 2009-09-23 Univ Johns Hopkins Compositions et méthodes de neuroprotection
US9289412B2 (en) 2006-08-11 2016-03-22 The Johns Hopkins University Role of limonoid compounds as neuroprotective agents
US9610276B2 (en) 2013-06-17 2017-04-04 Kgk Synergize, Inc. Compositions and methods for glycemic control of subjects with impaired fasting glucose

Also Published As

Publication number Publication date
AU2001232182A1 (en) 2002-07-24
WO2002055071A8 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
US20010055627A1 (en) Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols
US6251400B1 (en) Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
Terao Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function
Ganai et al. Bioactivity of genistein: A review of in vitro and in vivo studies
EP1014968B1 (fr) NARINGINE ET NARINGENINE UTILISEES EN TANT QU'INHIBITEUR DE 3-HYDROXY-3-METHYL-GLUTARYL COENZYME A (HMG CoA) REDUCTASE
Qureshi et al. Synergistic effect of tocotrienol-rich fraction (TRF25) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans
US4603142A (en) Cholesterol lowering method of use
Aggarwal et al. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases
US6544566B1 (en) Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
AU1404700A (en) Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6987125B1 (en) Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
Qureshi et al. The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens
US20020006953A1 (en) Modification of cholesterol concentrations with citus phytochemicals
US7090863B2 (en) Hypocholesterolemic composition and methods of use
US20050227930A1 (en) Cholesterol lowering combination
US20130165396A1 (en) Apple Skin Extracts for Treating Cardiovascular Disease
US20090156665A1 (en) Compositions Comprising Flavonoids and Toctrienols and Methods Thereof
WO2002055071A1 (fr) Compositions et methodes de regulation du taux de lipoproteines et de l'hypercholesterolemie au moyen de limonoides, de flavonoides et de tocotrienols
CA2350220C (fr) Composition antioxydante renfermant de la l-carnitine de propionyle et un flavonoide pour lutter contre la thrombose et l'atherosclerose
WO2001070029A1 (fr) Composition et methodes de traitement, de diminution, et de prevention de maladies et troubles cardio-vasculaires avec des polymethoxyflavones
US20040071800A1 (en) Method of reducing low density lipoprotein cholesterol concentration
Minami et al. The potential of sweet orange (Citrus sinensis) in cardiovascular health: A literature review
WO2013117007A1 (fr) Composition renfermant des phytostérols et du kudzu pour les maladies cardiovasculaires
Guthrie et al. Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
Minami et al. Jurnal Kedokteran dan Kesehatan Indonesia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 29/2002 UNDER (51) AFTER "A61K 31/365" REPLACE "A61K 31/353, A61K 31/353" BY "A61K 31/353, A61K 31/355"

Free format text: PAT. BUL. 29/2002 UNDER (51) AFTER "A61K 31/365" REPLACE "A61K 31/353, A61K 31/353" BY "A61K 31/353, A61K 31/355"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载